Reported Saturday, Protagonist's ICOTYDE Demonstrates Increasing PASI 100 Rates Through Week 52 And Nearly 60% Complete Skin Clearance In Adolescents In Phase 3 ICONIC Program

Protagonist's ICOTYDE has shown promising results in its Phase 3 ICONIC program, with one-year data indicating nearly 60% complete skin clearance in adolescents and increasing PASI 100 rates through week 52. The drug is noted for its favorable safety profile as a once-daily oral treatment for moderate-to-severe plaque psoriasis, distinguishing itself as the first and only IL-23 receptor-targeted oral peptide. Results will be presented at AAD 2026.